Analysis10k / Blog
EN한국어ES
Reverse DCF · LLY

What LLY's Stock Price Is Really Betting On

The short answer

At today's price, Eli Lilly's stock is pricing in roughly 42.6% annual free-cash-flow growth for the next ten years on a standard 3-year-average basis, at a 10% discount rate — though that figure drops to just 22.5% if trailing-twelve-month cash flow is used instead, nearly matching the company's actual 23.2% five-year revenue growth rate.

The conclusion

At its current price, LLY implies ~42.6% annual free-cash-flow growth for the next 10 years, discounted at 10%.

Eli Lilly's actual 5-year free-cash-flow growth has averaged 10.8% a year; revenue grew 23.2% a year over the same period.

Verdict: expectations far above track record — but read the fine print On the standard 3-year-average FCF base, the market's ask is well above anything Lilly has delivered. But this is a company whose free cash flow has been swinging wildly as new manufacturing capacity comes online, so which FCF figure you use as the starting point changes this conclusion dramatically — see the sensitivity section below before taking the headline number at face value.

Required growth vs. historical growth

Market's ask (base case, 3-yr avg FCF)
42.6%
Market's ask (TTM FCF basis)
22.5%
5-yr revenue CAGR (actual)
23.2%
5-yr FCF CAGR (actual)
10.8%

Required growth from the reverse DCF below. Historical CAGRs calculated from 10-K FY2021–FY2025.

For context, not part of this math Analyst consensus for 2026 revenue growth runs around 41.6% (web search, Yahoo Finance estimates) — a revenue growth figure, not a free-cash-flow one, so it isn't directly comparable to the reverse-DCF result, but it does suggest Wall Street's own near-term growth expectations aren't far from what the market's price implies.

Sensitivity: what if the discount rate moves?

Required growth by discount rate: 8% gives 36.5%, 9% gives 39.7%, 10% gives 42.6%, 11% gives 45.4%, 12% gives 48%36.5%8%39.7%9%42.6%10% (base)45.4%11%48%12%
Discount rate (bottom) vs. the growth the price then requires.
Required 10-year FCF growth by discount rate (WACC), base case
WACCRequired annual growth
8%36.5%
9%39.7%
10% (base case)42.6%
11%45.4%
12%48.0%

Across the full 8–12% range, the required growth rate stays between 36% and 48% on the base-case FCF figure — well above both of Lilly's 5-year historical growth rates.

What would move this number

  • Using the single most recent year's FCF ($8,972M, 2025) instead of the 3-year average ($4,508M) lowers the required growth rate to 32.5% at a 10% discount rate.
  • Using trailing-twelve-month FCF ($18,190M, H2 2025 + H1 2026) lowers the required growth rate all the way to 22.5% — almost exactly matching Lilly's actual 5-year revenue CAGR of 23.2%. This is the single input choice that flips the verdict from "far above track record" to "roughly in line."
  • In short, whether this looks like an unreasonable ask or a reasonable one depends entirely on which FCF base you choose — and Lilly's revenue and earnings are expanding so fast each quarter that there's no obvious "normal year" to anchor on.

Show your work

Five inputs, sources, model assumptions, and the calculation
  • Share price~$1,150 (approximate) — multiple web sources, mid-September 2026; not a real-time quote and subject to volatility
  • Diluted shares outstanding893.7M — 10-Q Q2 FY2026, as of June 30, 2026
  • Net debt$45.96B — total debt $54.91B (short-term $7.05B + long-term $47.86B) minus cash $8.95B, 10-Q Q2 FY2026
  • Base FCF (3-yr average)$4,508M — 10-K FY2023, FY2024, FY2025 cash flow statements (operating cash flow minus capex)
  • Discount rate (WACC)10% base case (8–12% tested); large-cap standard assumption

FCF normalization check: the most recent year's FCF ($8,972M, 2025) is 99% above the 3-year average ($4,508M) — well outside our ±40% normalization threshold. Per the standard rule, the 3-year average was used as the base case. But because this deviation reflects a structural high-growth phase rather than a one-time item, the TTM-based alternative is shown side by side above rather than dismissed.

Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter. Target enterprise value = market cap + net debt. We solve by bisection for the value of g that makes the present value of those cash flows equal that target. All calculations were run in code.

The fine print

This number is a starting point, not an answer
  • Change the discount rate, the projection window, the terminal growth rate, or—most importantly for this company—which FCF figure you normalize to, and the answer swings from 22.5% to 42.6%.
  • A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
  • Whether this growth is realistic depends on the Mounjaro/Zepbound franchise and the orforglipron pipeline holding up against competition — not on the math itself.
  • The share price used here is an approximation, not a real-time quote. Any investment decision, and its outcome, is your own responsibility.
Built from Eli Lilly's 10-K (FY2021–FY2025) and 10-Q (Q2 FY2026), plus a web search for an approximate current share price (mid-September 2026). This tells you where to dig deeper — it is not a buy or sell signal.

How this number is built, and how banks, REITs, and negative cash flow are handled: see our methodology.

Frequently asked questions

What growth rate does LLY's stock price assume?

On the standard 3-year-average free-cash-flow basis, Eli Lilly's current price implies roughly 42.6% annual free-cash-flow growth for the next ten years, discounted at a 10% rate.

Why does the required growth rate change so much depending on the calculation?

Eli Lilly's free cash flow has been swinging wildly as new manufacturing capacity comes online — using the trailing-twelve-month figure instead of the 3-year average lowers the required growth rate from 42.6% to just 22.5%, nearly matching the company's actual 5-year revenue growth of 23.2%.

What share price was used for this analysis?

This analysis used an approximate price of $1,150, based on multiple web sources from mid-September 2026 — not a real-time quote.